Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo
Go back to Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 118.52 +1.26 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $117.26 | 52 Week High | $118.49 | |||
| Open | $116.43 | 52 Week Low | $55.00 | |||
| Day High | $118.97 | P/E | N/A | |||
| Day Low | $116.43 | EPS | $-0.56 | |||
| Volume | 1,352,706 | |||||
